论文部分内容阅读
目的观察国产替罗非班对急性心肌梗死急诊冠状动脉介入治疗患者预后的影响。方法急性心肌梗死患者163例,随机分为对照组(82例)和替罗非班组(81例),比较两组基础临床资料、介入治疗情况、住院期间及6个月后主要心脏不良事件(MACE)发生率和安全性。结果两组患者基本临床资料和介入治疗情况差异均无统计学意义(P>0.05)。与对照组相比,替罗非班组住院期间及6个月后MACE的发生率明显降低(3.7%,17.1%;9.9%,22.0%)。两组的出血和血小板减少症发生率差异无统计学意义。结论国产替罗非班可显著降低急性心肌梗死直接经皮冠状动脉介入治疗后患者的住院期间和6个月MACE发生率,且不增加出血事件。
Objective To observe the effect of domestic tirofiban on the prognosis of patients with acute myocardial infarction undergoing coronary intervention. Methods A total of 163 acute myocardial infarction patients were randomly divided into control group (n = 82) and tirofiban group (n = 81). The basic clinical data, interventional treatment, hospitalization and major adverse cardiac events after 6 months MACE) incidence and safety. Results There was no significant difference in basic clinical data and interventional treatment between the two groups (P> 0.05). Compared with the control group, the incidence of MACE was significantly lower during hospitalization and after 6 months in the tirofiban group (3.7%, 17.1%; 9.9%, 22.0%). There was no significant difference in the incidence of hemorrhage and thrombocytopenia between the two groups. Conclusion Domestic tirofiban can significantly reduce the incidence of MACE during hospitalization and 6 months after direct percutaneous coronary intervention in patients with acute myocardial infarction without increasing the incidence of bleeding.